Your browser doesn't support javascript.
loading
Selective PP2A Enhancement through Biased Heterotrimer Stabilization.
Leonard, Daniel; Huang, Wei; Izadmehr, Sudeh; O'Connor, Caitlin M; Wiredja, Danica D; Wang, Zhizhi; Zaware, Nilesh; Chen, Yinghua; Schlatzer, Daniela M; Kiselar, Janna; Vasireddi, Nikhil; Schüchner, Stefan; Perl, Abbey L; Galsky, Matthew D; Xu, Wenqing; Brautigan, David L; Ogris, Egon; Taylor, Derek J; Narla, Goutham.
Afiliación
  • Leonard D; Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA; Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA.
  • Huang W; Department of Pharmacology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
  • Izadmehr S; Division of Hematology and Medical Oncology, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • O'Connor CM; Division of Genetic Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48105, USA; Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.
  • Wiredja DD; Department of Nutrition, Center for Proteomics and Bioinformatics, Case Western Reserve University, Cleveland, OH 44106, USA.
  • Wang Z; Department of Biological Structure, University of Washington, Seattle, WA 98195, USA.
  • Zaware N; Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Chen Y; PEPCC Facility, Case Western Reserve University, 10900 Euclid Ave., Cleveland, OH 44106, USA.
  • Schlatzer DM; Department of Nutrition, Center for Proteomics and Bioinformatics, Case Western Reserve University, Cleveland, OH 44106, USA.
  • Kiselar J; Department of Nutrition, Center for Proteomics and Bioinformatics, Case Western Reserve University, Cleveland, OH 44106, USA.
  • Vasireddi N; Department of Biology, Case Western Reserve University, Cleveland, OH 44106, USA.
  • Schüchner S; Center for Medical Biochemistry, Max Perutz Labs, Medical University of Vienna, Dr. Bohr-Gasse 9/2, Vienna 1030, Austria.
  • Perl AL; Department of Pharmacology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
  • Galsky MD; Division of Hematology and Medical Oncology, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Xu W; Department of Biological Structure, University of Washington, Seattle, WA 98195, USA.
  • Brautigan DL; Department of Microbiology, Immunology, and Cancer Biology, Center for Cell Signaling, University of Virginia, Charlottesville, VA 22903, USA.
  • Ogris E; Center for Medical Biochemistry, Max Perutz Labs, Medical University of Vienna, Dr. Bohr-Gasse 9/2, Vienna 1030, Austria.
  • Taylor DJ; Department of Pharmacology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA; Department of Biochemistry, Case Western Reserve University, Cleveland, OH 44106, USA. Electronic address: derek.taylor@case.edu.
  • Narla G; Division of Genetic Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48105, USA; Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA. Electronic address: gnarla@med.umich.edu.
Cell ; 181(3): 688-701.e16, 2020 04 30.
Article en En | MEDLINE | ID: mdl-32315618
Impairment of protein phosphatases, including the family of serine/threonine phosphatases designated PP2A, is essential for the pathogenesis of many diseases, including cancer. The ability of PP2A to dephosphorylate hundreds of proteins is regulated by over 40 specificity-determining regulatory "B" subunits that compete for assembly and activation of heterogeneous PP2A heterotrimers. Here, we reveal how a small molecule, DT-061, specifically stabilizes the B56α-PP2A holoenzyme in a fully assembled, active state to dephosphorylate selective substrates, such as its well-known oncogenic target, c-Myc. Our 3.6 Å structure identifies molecular interactions between DT-061 and all three PP2A subunits that prevent dissociation of the active enzyme and highlight inherent mechanisms of PP2A complex assembly. Thus, our findings provide fundamental insights into PP2A complex assembly and regulation, identify a unique interfacial stabilizing mode of action for therapeutic targeting, and aid in the development of phosphatase-based therapeutics tailored against disease specific phospho-protein targets.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteína Fosfatasa 2 Tipo de estudio: Prognostic_studies Límite: Animals / Humans / Male Idioma: En Revista: Cell Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteína Fosfatasa 2 Tipo de estudio: Prognostic_studies Límite: Animals / Humans / Male Idioma: En Revista: Cell Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos